健脾养胃方联合化疗对胃癌Ⅱ、Ⅲ期术后干预作用的临床研究

摘要

目的 研究健脾养胃方联合化疗对胃癌Ⅱ、Ⅲ期术后患者的临床干预作用.方法 将255例胃癌Ⅱ、Ⅲ期术后患者随机分为2组,试验组115例给予健脾养胃方联合FOLFOX4方案化疗,对照组140例给予单纯化疗.研究2组无病生存期、生命质量、中医征候疗效和胃癌相关肿瘤指标.结果 试验组患者半年和1年复发转移率、治疗3个月后骨髓抑制总发生率低于对照组,但差异无统计学意义；2组患者无病生存期比较差异有统计学意义；与治疗前比较,试验组治疗3个月后社会领域评分显著提高,治疗6个月后功能及恶心领域评分显著提高,与治疗3个月比较,治疗6个月后功能及经济领域评分显著提高；治疗6个月后,试验组骨髓抑制总发生率显著低于对照组.治疗3个月后,2组中医证候疗效分布相似,试验组治疗6个月后总有效率显著高于3个月后及对照组,而对照组治疗3、6个月后无变化.结论 健脾养胃方联合化疗治疗胃癌Ⅱ、Ⅲ期术后患者在延长无病生存期、降低复发转移率、提高生命质量、减轻化疗毒副反应等方面均具有不可替代的优势.%Objective To study the clinical intervention effects of Jianpi Yangwei Formula combined with chemotherapy on postoperative patients with gastric cancer at phases Ⅱ and Ⅲ. Methods A total of 255 postoperative patients with gastric cancer at phases Ⅱ and Ⅲ were randomly divided into 2 groups. The trial group (n = 115) received Jianpi Yangwei Formula combined with FOLFOX4 chemotherapy, while the control group (n - 140) received simple chemotherapy. Disease - free survival (DFS), quality of life, TCM syndrome therapeutic effects and tumor indexes related to gastric cancer of both groups were researched. Results Half - year, 1 - year relapse metastatic rates and total incidence of myelosuppression after three - month treatment in the trial group were lower than those in the control group, without striking differences. In comparison to DFS of both groups, there was significant difference. Compared with the previous treatment, the score of social field in the trial group 3 months after treatment markedly increased, and scores of functional and nausea fields also significantly elevated 6 months after treatment. Compared with three - month treatment, the scores of functional and economic fields notably increased 6 months after treatment. The total incidence of myelosuppression 6 months after treatment in the trial group was distinctly lower than that of the control group. After three - month treatment, the distributions of TCM syndrome therapeutic effects in both groups were similar. The total effectiveness rate of the trial group 6 months after treatment was conspicuously higher than those of 3 months after treatment and the control group, whereas there was no changes between three and six - month treatment in the control group . Conclusion Jianpi Yangwei Formula combined with chemotherapy for postoperative patients with gastric cancer at phases Ⅱ and Ⅲ has irreplaceable advantages in the aspects of prolonging DFS, reducing relapse metastatic rate, enhancing quality of life and alleviating chemotherapy - induced toxic and side reactions.